SCHEMBL2776812

SCHEMBL2776812

CCOC(=O)c1ncc2onc(-c3ccc(OC)cc3)c2c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 2/20 0.48
PDCD4 Q53EL6 1/20 0.48
JAK2 O60674 1/20 0.45
JAK3 P52333 1/20 0.45
HTT P42858 2/20 0.44
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
GABRA1 P14867 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41
PTGS2 P35354 3/20 0.41
PTGS1 P23219 1/20 0.41
PDE3A Q14432 1/20 0.41
IDO1 P14902 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2777575 0.89 SCN9A (0.47) TARBP2HTTALDH1A1POLBGABRA5
SCHEMBL2774763 0.89 CACNA2D1 (0.41) TARBP2PDCD4POLB
SCHEMBL2774483 0.88 TARBP2 (0.47) TARBP2JAK2JAK3ALDH1A1POLB
SCHEMBL2777192 0.88 SLC26A6 (0.46) ALDH1A1GAAGABRA5GABRA2PTGS2
SCHEMBL2777901 0.88 TARBP2 (0.47) TARBP2ALDH1A1POLBGABRA5GABRA2
SCHEMBL2776728 0.88 ALDH1A1 (0.46) TARBP2JAK2JAK3ALDH1A1POLB
SCHEMBL2776724 0.86 MLYCD (0.41) TARBP2JAK2JAK3HTTALDH1A1
SCHEMBL2775759 0.85 MLYCD (0.45) POLBGAAMEN1KMT2ANPC1
SCHEMBL2775944 0.85 PTGS2 (0.43) HTTALDH1A1PTGS2NPC1MAPT
SCHEMBL2773469 0.85 TP53 (0.42) ALDH1A1POLBGAAGABRA5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 TARBP2 4814/4885PDCD4 1962/4885JAK2 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.